i do not remind to read any launching-announcement by Norgine for launch in Germany, yet they now write:
LYMPHOSEEK®– a novel radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. LYMPHOSEEK® was launched in additional markets across Europe. It is available in Denmark, the Netherlands, the UK, GERMANY and Spain.
copied from here:
Norgine releases H1 2018 results
Strong performance in the first half of 2018 reflects the continued growth of Norgine’s leading brands as well as product revenues acquired through the acquisition of Merus Labs International Inc. (“Merus”)
Merus integration complete
AMSTERDAM, The Netherlands. 12 September 2018. 08:00 AM CST.
Norgine generated sales of €196 million in the first half of 2018 (H1 2018), 28% higher than in H1 2017. This growth was driven by the established products added by the acquisition of Merus (+ €32 million sales) and growth of Norgine’s key promoted products – particularly MOVICOL® and XIFAXAN® (+ €11million vs. H1 2017).
Norgine continues to drive performance of its products in Europe, Australia and New Zealand where it is investing for future growth.
MOVICOL®– the market leading treatment for constipation grew strongly year-on-year with sales of €79.0 million in H1 2018, up 6% from H1 2017
MOVIPREP®– Norgine’s 2 litre bowel preparation for colonoscopy – achieved sales of €29.8 million in H1 2018, up 5% from H1 2017
PLENVU®– the first 1 litre bowel preparation for colonoscopy received FDA approval in May 2018 and was launched in the US in September 2018. It is available through Norgine's infrastructure in Europe, Australia and New Zealand.
XIFAXAN® 550mg – for the treatment of hepatic encephalopathy – saw sales of €30 million in H1 2018, up 21% from H1 2017
LYMPHOSEEK®– a novel radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. LYMPHOSEEK® was launched in additional markets across Europe. It is available in Denmark, the Netherlands, the UK, Germany and Spain.
Significant key business developments
Following the acquisition of Merus in July 2017, the integration is now complete
Norgine continues its growth strategy and moved to a new office in Wettenberg, Germany. Germany is Norgine's largest market.
Peter Stein, CEO at Norgine said: “Our performance during the first half of 2018 demonstrates that our strategy is working. We are continuing to bring transformative products to market for the benefit of patients. The established products acquired through Merus and our promoted products, in particular MOVICOL® and XIFAXAN®, are key growth drivers for us. With the addition of PLENVU® to our product portfolio, we anticipate further growth in the remainder of 2018 and into 2019. Our success is a reflection of the hard work of our “One Norgine” team which has built a strong platform through which we can attract new opportunities for the benefit of patients.”
Notes to Editors:
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.